Non-small cell lung cancer stage III
Not yet recruitingDurvalumab personalized consolidation immunotherapy after chemoradiotherapy in patients with stage III non‑small cell lung cancer
Durvalumab personalized consolidation immunotherapy after chemoradiotherapy in patients with stage III non‑small cell lung cancer
- Disease:Non-small cell lung cancer stage III
- Substances:Durvalumab
France- Participants:18–64 years · 65+ years
- Substances:Durvalumab
- Sponsor:Intergroupe Francophone De Cancerologie Thoracique






